Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
PHAXIAM Therapeutics announces the validation of a new investigator-initiated…
A Phase 2 study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)Evaluation of the efficacy of a local treatment with PHAXIAM's anti- S. aureusphages added to the standard treatment by surgery and antibiotics 80 patients to be enrolled in 27 French clinical centersValidation of the study protocol by the ANSM expected in H1 2025 Lyon (France), October 9, 2024 – 06:00pm CEST - PHAXIAM Therapeutics...
Nasdaq GlobeNewswire
09/10/2024
Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of…
Centivax's Chief Executive Officer, Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of…
PR Newswire
09/10/2024
Proteotype Awarded £1.5 Million Grant to Advance Early Cancer Detection with…
While many cancer diagnostics rely on tumour-released signals, such as circulating tumour DNA, which is often only detectable once cancer has progressed, Enlighten® takes a different and potentially more powerful approach. It measures the host response to tumour development, tracking changing levels of proteins that occur even in the earliest stages of cancer. While many cancer diagnostics rely on tumour-released signals, such as circulating tumour DNA, which is often only detectable once...
PR Newswire
09/10/2024
Healthcare Analytics Market to Hit USD 133.19 Billion by 2029 with 24.3% CAGR |…
Browse in-depth TOC on "Healthcare Analytics Market" Browse in-depth TOC on "Healthcare Analytics Market" 150 - Tables50 - Figures350 - Pages Based on Component, the healthcare analytics market is segmented into services and software. The services segment held the largest market share in the healthcare analytics market due to increasing need for advanced analytical methods and tools for patient monitoring and treatment outcome improvement. As patient loads and disease...
PR Newswire
09/10/2024
Šarūnas Savičianskas is removed from the board of RADAS, UAB, and will be…
On October 9, 2024, MAXIMA GRUPĖ, UAB resolved to remove Šarūnas Savičianskas from the board of its subsidiary RADAS, UAB, and to appoint Jonas Jočys as the new board member, effective from October 10, until the end of the current board's term.RADAS, UAB board will consist of three members: Povilas Šulys, CEO of RADAS, UAB, Jolanta Bivainytė, CEO of MAXIMA LT, UAB, and Jonas Jočys, head of "Barbora" in Latvia and Estonia. Additional Information MAXIMA GRUPĖ, UAB manages retail…
Nasdaq GlobeNewswire
09/10/2024
Berite Labelle spotted at the Ritz Paris, surrounded by the biggest French…
With an eye for detail, Berite also had the bar manager of the Ritz, Romain de Courcy, create a cocktail with floral notes. With an eye for detail, Berite also had the bar manager of the Ritz,Romain de Courcy, create a cocktail with floral notes. Fostering a spirit of friendliness, elegance, and celebration, the evening, animated by the duo Doppelgänger, allowed guests to engage withBerite Labelleabout her new haute perfumery brand, as well as her activities as a model and...
PR Newswire
09/10/2024
ZEISS expands ophthalmic offerings to improve patient care with new digital AI…
"ZEISS continues to expand its digital leadership in ophthalmology, offering new, pioneering ophthalmic offerings and clinical tools that create an enhanced digital workflow experience for both patients and surgeons," said Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "With the foundation of our Health Data Platform as part of the ZEISS Medical Ecosystem, our data-driven healthcare solutions unlock enormous value for surgeons, helping them…
PR Newswire
09/10/2024
Global Health Exhibition to Unveil the World's Largest Virtual Hospital in…
"Global Health Exhibition sits at the forefront of medical advancement and technology, making the Virtual Hospital exhibit a perfect fit for attendees who are keen to understand the trajectory of healthcare services for the next decade and the increasing role virtual services play in reaching the widest possible group of patients," said Rachel Sturgess, Group Director, Tahaluf, the Exhibition's organiser. "Global Health Exhibition sits at the forefront of medical advancement and…
PR Newswire
09/10/2024
Greater Copenhagen Region makes relocation low-risk with the world's first "Life…
Greater Copenhagen Region, covering Eastern Denmark and Southern Sweden, consistently finishes at the top of global life quality surveys like the World Happiness Report. Particular praise is being given to the region's work-life balance, tolerant and trusting society, and exciting career opportunities. It's a winning formula for a happy life that they believe everyone should be able to try, no matter how risk-averse. Greater Copenhagen Region, coveringEastern DenmarkandSouthern Sweden,...
PR Newswire
09/10/2024
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical…
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform's unique potential in selecting effective vaccine targetsThe ongoing generation of relevant clinical data allows for continuous refinement of AI-Immunology™ thereby...
Nasdaq GlobeNewswire
09/10/2024
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for…
Designation is based on data from the clinical development program which demonstrated clinical proof of concept Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potential first-in-class therapeutic candidate for a range of rare immune-mediated indications with planning underway for Phase 3 developmentFDA Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and which have potential to show...
Nasdaq GlobeNewswire
09/10/2024
Invitation: Sobi's Q3 2024 report
Investors, analysts, and the media are invited to a conference call on the same day at 14:00 CEST, 13:00 BST, and 08:00 EDT. The call will include a presentation of the results and a Q&A session. Investors, analysts, and the media are invited to a conference call on the same day at14:00 CEST,13:00 BST, and08:00 EDT. The call will include a presentation of the results and a Q&A session. The presentation can be followed livehere or afterwards on sobi.com. The slides will be...
PR Newswire
09/10/2024
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to…
INTREPID's analysis shows that the majority of the 64 distinct direct-acting antiviral compounds in clinical phase studies target coronaviruses (SARS-CoV-2) and orthomyxoviruses (Influenza). Similarly, of the 96 distinct preclinical direct-acting antiviral compounds spanning the different stages of preclinical development, the majority target SARS-CoV-2 (COVID-19). Non-COVID-19 preclinical compounds under study are primarily targeting Influenza. Further analysis reveals that there is no…
PR Newswire
09/10/2024
Major shareholder announcement
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per October 7, 2024, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,189,675 shares, corresponding to 4.95% (previously 5.02%) of the total share capital attached to shares. The combined total of share...
Nasdaq GlobeNewswire
09/10/2024
SAUDI ENTERTAINMENT VENTURES (SEVEN) AND MATTEL BRING THRILLING HOT WHEELS…
Hot Wheels e-karts are engineered to push the limits of performance and are designed for the ultimate racing challenge. They combine competition, experimentation, safety, and creativity to provide thrilling vehicle challenges that develop the skills and confidence for kids to take on the world. The Hot Wheels e-karting experiences will be in SEVEN's entertainment complexes in Riyadh, Makkah, Taif, Al Madinah, Tabuk, and Jazan. Hot Wheels e-karts are engineered to push the limits of…
PR Newswire
09/10/2024
Technologies in Drug Discovery Informatics and Their Impact on the…
Allied Market Research
09/10/2024
Antag Therapeutics Announces FDA Clearance of Investigational New Drug (IND)…
AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous administration. Highly translational preclinical studies have shown that AT-7687 attenuates weight gain and enhances GLP-1-mediated weight loss while improving lipid profiles, particularly LDL, independent of weight change. Importantly, these benefits are not associated with gastrointestinal side effects. The upcoming Phase I trial will assess safety, tolerability, and pharmacokinetics of AT-7687 alone and in…
PR Newswire
09/10/2024
Curve Therapeutics continues to enhance leadership team with appointment of Rab…
Curve's mission is to improve patient outcomes by discovering innovative drugs that address the most challenging and complex disease targets. Rab will be responsible for the therapeutic portfolio strategy to advance the Company's growing pipeline of first-in-class assets, including a dual HIF-1/HIF-2 inhibitor and an inhibitor of ATIC homodimerization. He will also leverage his expertise in oncology, neuroscience, immunology and epigenetics to further enhance target selection and validation…
PR Newswire
09/10/2024
Purespring Therapeutics raises £80/$105 million in a Series B financing to…
Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseasesOversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targetingIgA Nephropathy (IgAN) London – 9 October 2024 -...
Nasdaq GlobeNewswire
09/10/2024
Wheeler Bio Appoints Industry Veteran Patrick Lucy as Chief Executive Officer
"We are thrilled to welcome Patrick to the Wheeler team," said Jesse McCool, Ph.D., Co-Founder and Chief Scientific Officer of Wheeler Bio. "His impressive track record of establishing and scaling biotechnology organizations make him the right leader to guide Wheeler as we transition to a fully integrated commercial-scale CDMO." "We are thrilled to welcome Patrick to the Wheeler team," saidJesse McCool, Ph.D., Co-Founder and Chief Scientific Officer of Wheeler Bio…
PR Newswire
09/10/2024
Press Release: New Beyfortus data featured at IDWeek reinforce real-world…
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America's IDWeek 2024 annual meeting in Los Angeles, California, from October 16-19, 2024.Thomas Triomphe Executive Vice President, Vaccines,...
Nasdaq GlobeNewswire
09/10/2024
DAHON & RoyalBaby Unveils New Strategic Partnership
"As DAHON and RoyalBaby have accumulated a wealth of knowledge and outstanding performance in their respective fields, this strategic cooperation will surely set a new benchmark for the industry. I sincerely hope that this cooperation can drive more enterprises to actively explore their frontier of innovation and jointly promote the sustainable and healthy development of China's toy and baby products industry.", said Ms. Liang Mei, President of the China Toy and Juvenile Products…
PR Newswire
09/10/2024
AWAK Transforms into Vivance, Unveiling a New Brand Identity
Suresha Venkataraya, CEO of Vivance, said, "This rebrand reflects how far we've come, and where we're heading. Building on the foundation of our wearable dialysis device, we've made significant strides by expanding our portfolio to include cost-effective home modalities and complementary digital offerings. This rebrand reinforces our ultimate mission of treating patients in the comfort of their homes." Suresha Venkataraya, CEO of Vivance, said, "This rebrand reflects how far we've…
PR Newswire
09/10/2024
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital…
Company announcement – No. 48 / 2024 Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspectionThe reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pendingZealand remains committed...
Nasdaq GlobeNewswire
09/10/2024
Altri Comunicati
